sphingosine-1-phosphate has been researched along with Peripheral-Nervous-System-Diseases* in 2 studies
1 review(s) available for sphingosine-1-phosphate and Peripheral-Nervous-System-Diseases
| Article | Year |
|---|---|
The ceramide-S1P pathway as a druggable target to alleviate peripheral neuropathic pain.
Topics: Animals; Ceramides; Drug Development; Humans; Lysophospholipids; Molecular Targeted Therapy; Peripheral Nervous System Diseases; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysophosphatidic Acid; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
1 other study(ies) available for sphingosine-1-phosphate and Peripheral-Nervous-System-Diseases
| Article | Year |
|---|---|
Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy.
Platinum-based therapeutics are used to manage many forms of cancer, but frequently result in peripheral neuropathy. Currently, the only option available to attenuate chemotherapy-induced neuropathy is to limit or discontinue this treatment. Sphingosine 1-phosphate (S1P) is a lipid-based signaling molecule involved in neuroinflammatory processes by interacting with its five cognate receptors: S1P Topics: Animals; Antineoplastic Agents; Axons; Biomarkers; Cisplatin; Female; Humans; Lysophospholipids; Myelin Sheath; Neuroglia; PC12 Cells; Peripheral Nervous System Diseases; Platinum; Rats; Rats, Sprague-Dawley; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors | 2020 |